EOC 317

Drug Profile

EOC 317

Alternative Names: ACTB-1003; EDP317; EOC317; MMKI - ACT Biotech; Multi-mode kinase inhibitor - ACT Biotech

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer ACT Biotech; Eddingpharm
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Fibroblast growth factor receptor antagonists; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Cancer

Most Recent Events

  • 29 May 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT03583125)
  • 26 Jan 2018 EOC 317 receives Clinical trial approval for Cancer in China before January 2018
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top